Skip to main content
SpringerLink
Log in

Therapy of Autoimmune Connective Tissue Diseases

  • Chapter
Therapeutic Immunosuppression

Part of the book series: Immunology and Medicine Series ((IMME,volume 29))

  • 113 Accesses

Abstract

The autoimmune diseases can be divided into two basic categories: organ specific and systemic. Organ specific autoimmune disease can affect virtually any tissue of the body and is associated most often with evidence of both T and B cell autoimmune responses directed against the cells of the affected organ. Examples of organ specific autoimmune disease include multiple sclerosis, Type I diabetes mellitus, Grave’s disease, autoimmune hemolytic anemia, and myasthenia gravis, which affect the central nervous system, pancreatic β-cells, thyroid gland, erythrocytes, and cholinergic neuromuscular junctions, respectively. The systemic autoimmune diseases, also referred to as connective tissue diseases (CTD), comprise a group of illnesses in which multiple organ system damage is a common characteristic. These diseases are also related in that they can share autoantibody specificities and have overlap in organ system involvement as well as in clinical features. The CTD group includes systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), idiopathic inflammatory myopathies (polymyositis and dermatomyositis), and systemic vasculitides (e.g. Wegener’s granulomatosus and polyarteritis nodosa).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Langford CA, Klippel JH, Balow JE, James SP, Sneller MC. Use of Cytotoxic Agents and Cyclosporine in the Treatment of Autoimmune Disease: Part I Rheu-matologie and Renal Diseases. Ann Int Med 1998; 128:1021–1028.

    PubMed  CAS  Google Scholar 

  2. Langford CA, Klippel JH, Balow JE, James SP, Sneller MC. Use of Cytotoxic Agents and Cyclosporine in the Treatment of Autoimmune Disease: Part 2: Inflammatory Bowel Disease, Systemic Vasculitis, and Therapeutic Toxicity. Ann Int Med 1998; 129:49–58.

    PubMed  CAS  Google Scholar 

  3. Ballow M, Nelson R. Immunopharmacology: Immunomodulation and Immuno-therapy. JAMA 1997; 278:2008–2017.

    Article  PubMed  CAS  Google Scholar 

  4. Angelí A, Masera RG, Sartori ML, Fortunati N, Racca S., Dovio A, Staurenghi A, Frairia R. Modulation by Cytokines of Glucocorticoid Action. Ann N Y Acad Sci 1999; 210–220.

    Google Scholar 

  5. Morand EF. Corticosteroids in the treatment of rheumatologic diseases. Curr Opin Rheum 1998; 10:179–183.

    Article  CAS  Google Scholar 

  6. Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V, Kirschbaum BJ. Mechansim of action for leflunomide in rheumatoid arthritis 1999; Clin Immunol 93:198–208.

    Google Scholar 

  7. Sievers TM, Rossi SJ, Ghobrial RM, Arriola E, Nishimura P, Kwano M, Holt CD. Mycophenolate mofetil. Pharmacotherapy 1997;17:1178–1197.

    PubMed  CAS  Google Scholar 

  8. Li E, Brooks P, Conaghan PG. Disease-modifying antirheumatic drugs. Curr Opin Rheum.1998; 10:159–168.

    Article  CAS  Google Scholar 

  9. Wolfe F, Hawley DJ, Cathey MA: Termination of slow-acting antirheumatic therapy in rheumatoid arthritis: a 14 year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17: 994–1002

    PubMed  CAS  Google Scholar 

  10. Felson DT, Anderson JJ, Meenan RF: Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: A meta-analysis of published clinical trials. Arthritis Rheum 1992; 35: 1117–1125

    Article  PubMed  CAS  Google Scholar 

  11. Fries JF, Williams CA, Ramey D, Bloch DA: The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993; 36: 297–306

    Article  PubMed  CAS  Google Scholar 

  12. Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Derm 1999; 135: 54–56.

    Article  PubMed  CAS  Google Scholar 

  13. Corna D, Morigi M, Facchinetti D, Bertani T, Zoja C, Remuzzi G. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 1997; 51:1583–1589.

    Article  PubMed  CAS  Google Scholar 

  14. Jonsson CA, Svensson L, Carlsten H. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice. Clin Exp Immunol 1999;116:534–541.

    Article  PubMed  CAS  Google Scholar 

  15. Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kid Dis 1998; 32:318–322.

    Article  PubMed  CAS  Google Scholar 

  16. Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999; 8:731–736.

    Article  PubMed  CAS  Google Scholar 

  17. Jarvinen P, Aho K. Twin studies in rheumatic diseases. Sem Arth Rheum. 1994; 24:19–28.

    Article  CAS  Google Scholar 

  18. Silman AJ, MacGregor A, Thomson W, et al. Twin concordance rates for rheumatoid arthritis: results of a nationwide study. Br J Rheum 1993; 32: 903–907.

    Article  CAS  Google Scholar 

  19. Grennan DM, Parfitt A, Manolios N, Huang Q, Hyland V, Dunckley H, Doran T. Gatenby P, Badcock C. Family and twin studies in systemic lupus erythematosus. Dis Markers. 1997;13:93–98.

    PubMed  CAS  Google Scholar 

  20. Marmont AM, van Lint MT, Gualandi F, Bacigalupo A. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus. 1997; 6:545–548.

    Article  PubMed  CAS  Google Scholar 

  21. Burt RK, Georganas C, Schroeder J, et al. Autologous hematopoietic stem cell transplantation in refractory rheumatoid arthritis. Arth Rheum. 1999; 42: 2281–2285.

    Article  CAS  Google Scholar 

  22. Burt RK, Traynor AE, Pope R, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood. 1998; 92:3505–3514.

    PubMed  CAS  Google Scholar 

  23. Traynor A, Burt RK. Haematopoietic stem cell transplantation for active systemic lupus erythematosus. Rheumatology. 1999; 38:767–772.

    Article  PubMed  CAS  Google Scholar 

  24. Fouillard L, Gorin NC, Laporte JP, Leon A, Brantus JF, Miossec P. Control of severe systemic lupus erythematosus after high-dose immunusuppressive therapy and transplantation of CD34+ purified autologous stem cells from peripheral blood. Lupus. 1999; 8:320–323.

    Article  PubMed  CAS  Google Scholar 

  25. Wulffraat N, van Royen A, Bierings M, Vossen J, Kuis W. Autologous haemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis Lancet. 1999; 353:550–553.

    Article  PubMed  CAS  Google Scholar 

  26. Brodsky RA, Petri M, Smith BD, et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Int Med 1998;129:1031–1035.

    PubMed  CAS  Google Scholar 

  27. Nousari HC, Brodsky RA, Jones RJ, Grever MR, Anhalt GJ. Immunoablative highdose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus. J Am Acad Derm. 1999; 40:750–754.

    Article  PubMed  CAS  Google Scholar 

  28. Paavonen T. Hormonal regulation of immune responses. Ann Med 1994; 26: 255–258.

    Article  PubMed  CAS  Google Scholar 

  29. Olsen NJ, Kovacs WJ. Gonadal steroids and immunity. Endocrine Rev 1996; 17: 369–384.

    CAS  Google Scholar 

  30. Cutolo M, Sulli A, Seriólo B, Accardo S, Masi AT. Estrogens, immune response and autoimmunity. Clin Exp Immunol 1995; 13:217–226.

    CAS  Google Scholar 

  31. Sthoeger ZM, Bentwich Z, Zinger H, Mozes E. The beneficial effect of the estrogen antagonist Tamoxifen, on experimental systemic lupus erythematosus. J Rheumatol 1994; 21:2231–2238.

    PubMed  CAS  Google Scholar 

  32. Dayan M, Zinger H, Kalush F, Mor G, Amir-Zaltzman Y, Kohen F. The beneficial effects of treatment with tamoxifen and anti-oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations. Immunology 1997; 90:101–108.

    Article  PubMed  CAS  Google Scholar 

  33. Sturgess AD, Evans DT, Mackay IR, Riglar A. Effects of the oestrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus. J Clin Lab Immunol 1984; 12:11–14.

    Google Scholar 

  34. Kanai Y, Takeda O, Miura K, Kurosawa Y. Novel autoimmune phenomena induced by a recombinant nucleobindin that has a long leucine zipper structure. Arthritis Rheum 1992; 35:S207.

    Google Scholar 

  35. Strand V. Biologic agents and innovative interventional approaches in the management of systemi lupus erythematosus. Curr Opin Rheumatol 1999; 11: 330–340.

    Article  PubMed  CAS  Google Scholar 

  36. Petri M, Lahita R, McGuire J, et al. Results of the GL701 (DHEA) multicenter steroid-sparing SLE study. Arthritis Rheum 1997; 40:S326

    Article  Google Scholar 

  37. McMurray RW. Prolactin and systemic lupus erythematosus. Ann Med Interne 1996; 147:253–258.

    CAS  Google Scholar 

  38. Elbourne KB, Keisler D, McMurray RW. Differential effects of estrogen and prolactin on autoimmune disease in the NZB/NZW Fl mouse model of systemic lupus erythematosus. Lupus 1998; 7: 420–427.

    Article  PubMed  CAS  Google Scholar 

  39. Reber PM. Prolactin and immunomodulation. Amer J Med 1993; 95:637–644.

    Article  PubMed  CAS  Google Scholar 

  40. Alvarez-Nemegyei J, Cobarrubias-Cobos A, Escalante-Triay F, Sosa-Munoz J, Miranda JM, Jara LJ. Bromocriptine in systemic lupus erythematosus: a doubleblind, randomized, placebo-controlled study. Lupus 1998; 7:414–419.

    Article  PubMed  CAS  Google Scholar 

  41. Halloran, PF. Molecular mechanisms of new immunosuppressants. Clin Transplant 1996; 10:118–123.

    PubMed  CAS  Google Scholar 

  42. Henry M L. Cyclosporine and tacrolimus (FK506): A comparison of efficacy and safety profiles. Clin Transplant 1999; 13:209–220.

    Article  PubMed  CAS  Google Scholar 

  43. Blank M. Ben-Bassat M. Shoenfeld Y. The effect of cyclosporin A on early and late stages of experimental lupus. Arthritis Rheum 35:1350–5, 1992

    PubMed  CAS  Google Scholar 

  44. Entani C, Izumino K, Iida H, Fujita M, Asaka M, Takata M, Sasayama S. Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ lpr/lprmice. Nephron. 1993; 64:471–475.

    Article  PubMed  CAS  Google Scholar 

  45. Woo J, Wright TM, Lemster B, Borochovitz D, Nalesnik MA, Thomson AW. Combined effects of FK506 (tacrolimus) and cyclophosphamide on atypical B220+ T cells, cytokine gene expression and disease activity in MRL/MpJ-lpr/lpr mice. Clin Exp Immunol. 1995; 100:118–125.

    Article  PubMed  CAS  Google Scholar 

  46. Furukawa F, Imamura S, Takigawa M. FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr mice. Arch Derm Res. 1995; 287:558–563.

    Article  PubMed  CAS  Google Scholar 

  47. Burkhardt H, Kalden JR. Xenobiotic immunosuppressive agents: therapeutic effects in animal models of autoimmune diseases. Rheum Int. 1997; 17:85–90.

    Article  CAS  Google Scholar 

  48. Sullu Y, Oge I, Erkan D, Ariturk N, Mohajeri F. Cyclosporin-A therapy in severe uveitis of Behcet’s disease. Acta Ophth Scand 1998; 76:96–99.

    Article  CAS  Google Scholar 

  49. Cush JJ, Tugwell P, Weinblatt M, Yocum D. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. J Rheum.1999; 26:1176–1186.

    PubMed  CAS  Google Scholar 

  50. Lightman S. New therapeutic options in uveitis. Eye. 1997; 11:222–226.

    Article  PubMed  Google Scholar 

  51. Duddridge M, Powell RJ. Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 1997; 56:690–692.

    CAS  Google Scholar 

  52. Gremillion RB, Posever JO, Manek N, West JP, van Volen-Hoven RF. Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis J Rheum. 1999; 26:2332–2336.

    PubMed  CAS  Google Scholar 

  53. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyosi-tis with interstitial lung disease. Lancet. 1999; 353:1762–1763.

    Article  PubMed  CAS  Google Scholar 

  54. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Thl, Th2 and more. Immunology Today 1996;17:138–146.

    Article  PubMed  CAS  Google Scholar 

  55. Wallis WJ, Fürst DE, Strand V, Keystone E. Biologic agents and immunotherapy in rheumatoid arthritis. Progress and perspective. Rheum Dis Clin N Amer 1998; 24:537–565.

    Article  CAS  Google Scholar 

  56. Röcken M, Shevach EM. Immune deviation—the third dimension of nondeletional T-cell tolerance. Immunol Rev 1996; 149: 175–194.

    Article  PubMed  Google Scholar 

  57. Jorgensen C, Apparailly F, Sany J. Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt? Ann Rheum Dis 1999; 58:136–141.

    Article  PubMed  CAS  Google Scholar 

  58. Keystone E, Wherry J, Grint P. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum Dis Clin N Amer 1998; 24:629–639.

    Article  CAS  Google Scholar 

  59. Brennan FM, Feldman M. Cytokines in autoimmunity. Curr Opin Immunol 1996; 8:872–877.

    Article  PubMed  CAS  Google Scholar 

  60. Persson S, Mikulowska A, Narula S, O’Garra A, Holmdahl R. Interleukin-10 suppresses the development of collagen type n-induced arthritis and ameliorates sustained arthritis in rats. Scand J Immunol 1996; 44:607–614.

    Article  PubMed  CAS  Google Scholar 

  61. Crisi GM, Santamgrogio L, Hochwald GM, et al. Staphylococcal enterotoxin B and tumor-necrosis factor-alpha-induced relapses of experimental allergic encephalomyelitis: protection by transforming growth factor-beta and interleukin-10. Euro J Immunol 1995; 25:3035–3040.

    Article  CAS  Google Scholar 

  62. Walmsley M, Katsikis PD, Abney E, et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996; 39:495–503.

    Article  PubMed  CAS  Google Scholar 

  63. Heresbach D, Semana G, Gosselin M, Bretagne MG. An immunomodulation strategy targeted towards immunocompetent cells or cytokines in inflammatory bowel diseases. Europ Cytokine Network 1999; 10: 7–15.

    CAS  Google Scholar 

  64. Jorgensen C, Apparailly F, Couret I, Canovas F, Jacquet C, Sany J. Interleukin-4 and interleukin-10 are chondroprotective and decrease mononuclear cell recruitment in human rheumatoid synovium in vivo. Immunology 1998; 93:518–523.

    Article  PubMed  CAS  Google Scholar 

  65. Caspi RR. IL-12 in autoimmunity. Clin Immunol Immunopathol 1998; 88:4–13.

    Article  PubMed  CAS  Google Scholar 

  66. Weckmann AL, Alcocer-Várela J. Cytokine inhibitors in autoimmune disease. Semin Arthritis Rheum 1996; 26:539–557.

    Article  PubMed  CAS  Google Scholar 

  67. Allen JB, Wong HL, Costa GL, Bienkowski MJ, Wahl SM. Suppression of monocyte function and differential regulation of IL-1 and IL-lra by IL-4 contribute to resolution of experimental arthritis. J Immunol 1993; 151:4344–4351.

    PubMed  CAS  Google Scholar 

  68. Joosten LAB, Lubberts E, Durez P, et al. Role of interleukin-4 and interleuMn-10 in murine collagen-induced arthritis: protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997; 40: 249–260.

    Article  PubMed  CAS  Google Scholar 

  69. Li DKB, Paty DW, The UBCMS/MRI Analysis Research Group, The PRISMS Study Group. Magnetic resonance imaging results of the PRISMS Trial: A randomized, double-blind, placebo-controlled study of interferon-[beta]la in relapsing-remitting multiple sclerosis. Ann Neurol 1999; 46:197–206.

    Article  PubMed  CAS  Google Scholar 

  70. Anonymous. Randomised double-blind placebo-controlled study of interferon beta-la in relapsing/remitting multiple sclerosis. Lancet 1998; 352:1498–1504.

    Article  Google Scholar 

  71. Ruuls SR, Sedgwick JD. Cytokine-directed therapies in multiple sclerosis and experimental autoimmune encephalomyelitis. Immunol Cell Biol 1998; 76:65–73.

    Article  PubMed  CAS  Google Scholar 

  72. Rep MHG, Schrijver HM, van Lopik T, et al. Interferon (IFN)-β treatment enhances CD95 and interleukin 10 expression but reduces interferon-γ producing T cells in MS patients. J Neuroimmunol 1999; 96:92–100.

    Article  PubMed  CAS  Google Scholar 

  73. Turner M, Chantry D, Katsikis P, Berger A, Brennan FM, Feldmann M. Induction of the interleukin 1 receptor antagonist protein by transforming growth factorbeta. Euro J Immunol 1991; 21:1635–1639.

    Article  CAS  Google Scholar 

  74. Dubois CM, Ruscetti FW, Palaszynski EW, Falk LA, Oppenheim JJ, Keller JR. Transforming growth factor beta is a potent inhibitor of interleukin 1 (IL-1) receptor expression: proposed mechanism of inhibition of IL-1 action. J Exp Med 1990; 172:737–744.

    Article  PubMed  CAS  Google Scholar 

  75. Kuruvilla AP, Shah R, Hochwald GM, Liggitt HD, Palladino MA, Thorbecke GJ. Protective effect of transforming growth factor beta-1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci (USA) 1991; 88:18–21.

    Article  Google Scholar 

  76. Kavanaugh AF. Anti-tumor necrosis factor-a monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998; 24:593–614.

    Article  PubMed  CAS  Google Scholar 

  77. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci (USA) 1975; 72:3666–3670.

    Article  CAS  Google Scholar 

  78. Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 ceUs. J Exp Med 1985; 161:984–995.

    CAS  Google Scholar 

  79. Kollias G, Douni E, Kassiotis G, Kontoyiannis D. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev. 1999; 169:175–194.

    Article  PubMed  CAS  Google Scholar 

  80. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology. 1992; 77:510–514.

    PubMed  CAS  Google Scholar 

  81. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci (USA). 1992; 89: 9784–9788.

    Article  CAS  Google Scholar 

  82. Joosten LA. Helsen MM. van de Loo FA. van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. Arthritis Rheum. 1996; 39:797–809.

    Article  PubMed  CAS  Google Scholar 

  83. Moreland LW. Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998; 24:579–591.

    Article  PubMed  CAS  Google Scholar 

  84. Moreland LW, Baumgartner SW, Schiff MH, et al: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New Engl J Med 1997; 337: 141–147.

    Article  PubMed  CAS  Google Scholar 

  85. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CGT, Lang M, Bürge DJ: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc protein, in patients with rheumatoid arthritis receiving methotrexate. New Engl J Med 1999; 340: 253–259.

    Article  PubMed  CAS  Google Scholar 

  86. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic eff icacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41:1552–1563.

    Article  PubMed  CAS  Google Scholar 

  87. van der Meer JW, Vogels MT, Netea MG, Kullberg BJ. Proinflammatory cytokines and treatment of disease. Ann N Y Acad Sci. 1998; 856:243–251.

    Article  PubMed  Google Scholar 

  88. Warren JS. Cytokines in autoimmune disease. Clin Lab Med 1997; 17:547–557.

    PubMed  CAS  Google Scholar 

  89. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagnoist. J Clin Invest 1990; 85:1694–1697.

    Article  PubMed  CAS  Google Scholar 

  90. Otani K, Nita I, Macaulay W, Gerogescu HI, Robbins PD, Evans CH. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol 1996; 156:3558–3562.

    PubMed  CAS  Google Scholar 

  91. Makarov SS, Olsen JC, Johnston WN, et al. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Nat’l Acad Sci USA 1996; 93:402–406.

    Article  CAS  Google Scholar 

  92. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41:2196–204.

    Article  PubMed  CAS  Google Scholar 

  93. Drevlow BE, Lovis R, Haag MA, et al. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1996; 39:257–265.

    Article  PubMed  CAS  Google Scholar 

  94. Cohick CB, Fürst DE, Quagliata S, Corcoran KA, Steere KJ, Yager JG, Lindsley HB. Analysis of elevated serum interleukin-6 levels in rheumatoid arthritis: correlation with erythrocyte sedimentation rate or C-reactive protein. J Lab Clin Med. 1994; 123:721–7.

    PubMed  CAS  Google Scholar 

  95. Wendung D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. Journal of Rheumatology. 1993; 20: 259–262.

    Google Scholar 

  96. Mihara M, Kotoh M, Oda, et al. Anti-II-6 receptor antibody suppresses the onset of collagen arthritis in monkeys. Arthritis Rheum 1997;40: S133.

    Google Scholar 

  97. Mclntyre KW, Shuster DJ, Gillooly KM, et al. Reduced incidence and severity of collagen-induced arthritis in interleukin-12-deficient mice. Euro J Immunol 1996; 26:2933–2938.

    Article  Google Scholar 

  98. Malfait AM, Butler DM, Presky DH, Maini RN, Brennan FM, Feldman M. Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol 1998; 111:377–383.

    Article  PubMed  CAS  Google Scholar 

  99. Davidson NJ, Hudak SA, Lesley RE, Menon S, Leach MW, Rennick DM. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol 1998; 161:143–149.

    Google Scholar 

  100. Constantinescu CS, Wysocka M, Hilliard B, et al. Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. J Immunol 1998; 161:5097–5104.

    PubMed  CAS  Google Scholar 

  101. Butler DM, Malfait AM, Maini RN, Brennan FM, Feldman M. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collageninduced arthritis. Euro J Immunol 1999; 29:2205–2212.

    Article  CAS  Google Scholar 

  102. Sperling AI, Bluestone JA. The complexities of T-cell co-stimulation: CD28 and beyond. Immunol Rev. 1996;153:155–182.

    Article  PubMed  CAS  Google Scholar 

  103. McAdam AJ, Schweitzer AN, Sharpe AH. The role of B27 costimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol Rev 1998; 165: 231–247.

    Article  PubMed  CAS  Google Scholar 

  104. Nakajima A, Azuma M, Kodera S, et al. Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule. Euro J Immunol 1995; 25:3060–3069.

    Article  CAS  Google Scholar 

  105. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994; 265:1225–1227.

    Article  PubMed  CAS  Google Scholar 

  106. Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103: 1243–1252.

    Article  PubMed  CAS  Google Scholar 

  107. van Kooten C, Banchereau J. Functional role of CD40 and its ligand. Int Arch Allergy Immunol 1997; 113:393–399.

    Article  PubMed  Google Scholar 

  108. van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol 1997; 9:330–337.

    Article  PubMed  Google Scholar 

  109. Aruffo A, Farrington M, Hollenbaugh D, et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993; 72:291–300.

    Article  PubMed  CAS  Google Scholar 

  110. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noëlle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993;261:1328–1330.

    Article  PubMed  CAS  Google Scholar 

  111. Gerritse K, Laman JD, Noelle RJ, et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Nat Acad Sci USA 1996; 93:2499–2504.

    Article  PubMed  CAS  Google Scholar 

  112. Balasa B, Krahl T, Patstone G, et al. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 1997; 159:4620–4627.

    PubMed  CAS  Google Scholar 

  113. Mohan C, Shi Y, Laman JD, Dattta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995; 154: 1470–1480.

    PubMed  CAS  Google Scholar 

  114. Early GS, Zhao W, Burns CM. Anti-CD 40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. J Immunol 1996; 157:3159–3164.

    PubMed  CAS  Google Scholar 

  115. Durie FH, Aruffo A, Ledbetter J, et al. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J Clin Invest 1994; 94:1333–1338.

    Article  PubMed  CAS  Google Scholar 

  116. Datta SK, Kalled SL. CD40-CD40 ligand interaction in autoimmune disease. Arthritis Rheum 1997; 40:1735–1745.

    Article  PubMed  CAS  Google Scholar 

  117. Kalled SL, Cutler AH, Datta SK, Thomas DW. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol 1998; 160:2158–2165.

    PubMed  CAS  Google Scholar 

  118. Weinberg AD, Wegmann KW, Funatake C, Whitham RH. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol 1999; 162: 1818–1826.

    PubMed  CAS  Google Scholar 

  119. Weinberg AD, Lemon M, Jones AJ, et al. OX-40 antibody enhances for autoantigen specific V beta 8.2+ T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis. J Neurosci Res 1996; 43:42–49.

    Article  PubMed  CAS  Google Scholar 

  120. Oppenheimer-Marks N, Lipsky PE. Adhesion molecules as targets for the treatment of autoimmune diseases. Clin Immunol Immunopathol 1996; 79:201–210.

    Article  Google Scholar 

  121. Foster CA. VCAM-l/[alpha]4-integrin adhesion pathway: therapeutic target for allergic inflammatory disorders. J Allergy Clin Immunol 1999;98:270–277.

    Article  Google Scholar 

  122. Kootstra CJ, Van Der Giezen DM, Van Krieken JHJM, De Heer E, Bruijn JA. Effective treatment of experimental lupus nephritis by combined administration of anti-CDlla and anti-CD54 antibodies. Clin Exp Immunol 1997; 108:324–332.

    Article  PubMed  CAS  Google Scholar 

  123. Bowen JD, Petersdorf SH, Richards TL, et al. Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis. Clin Pharmacol Ther 1998; 64: 339–346.

    Article  PubMed  CAS  Google Scholar 

  124. Kavanaugh AF, Davis LS, Jain RI, Nichols LA, Norris SH, Lipsky PE. A phase I/II open label study of the safety and efficacy of an anti-ICAM-1. J Rheumatol 1996; 23:1338–1344.

    PubMed  CAS  Google Scholar 

  125. Kavanaugh AF, Davis LS, Nichols LA, et al. Treatment of refractory rheumatoid with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994; 37:992–999.

    Article  PubMed  CAS  Google Scholar 

  126. Kavanaugh AF, Schulze-Koops H, Davis LS, Lipsky PE. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum 1997; 40:849–853.

    Article  PubMed  CAS  Google Scholar 

  127. Orosz CG, Ohye RG, Pelletier RP, et al. Treatment with anti-vascular cell adhesion molecule 1 monoclonal antibody induces long-term murine cardiac allograft acceptance. Transplantation 1993; 56:453–460.

    Article  PubMed  CAS  Google Scholar 

  128. Tsukamoto K, Yokono K, Amano K, et al. Administration of monoclonal antibodies against vascular cell adhesion molecule-1/very late antigen-4 abrogates predisposing autoimmune diabetes in NOD mice. Cell Immunol 1995; 165:193–201.

    Article  PubMed  CAS  Google Scholar 

  129. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356:63–66.

    Article  PubMed  CAS  Google Scholar 

  130. Soilu-Hänninen M, Röyttä M, Salmi A, Salonen R. Therapy with antibody against leukocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis. J Neuroimmunol 1997; 72:95–105.

    Article  PubMed  Google Scholar 

  131. Breedveld FC. Monoclonal antibodies to CD4. Rheum Dis Clin N Amer 1998; 24:567–577.

    Article  CAS  Google Scholar 

  132. Choy EH, Chikanza IC, Kingsley GH, Corrigall V, Panayi GS. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scan J Immunol 1992; 36:291–298.

    Article  CAS  Google Scholar 

  133. Choy EH, Pitzalis C, Cauli A, et al. Percentage of anti-CD4 monoclonal antibodycoated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens. Arthritis Rheum 1996; 39:52–56.

    CAS  Google Scholar 

  134. Panayi GS, Choy EHS, Connolly DJA, et al. T cell hypothesis in rheumatoid arthritis (RA) tested by humanized non-depleting anti-CD4 monoclonal antibody (mAb) treatment I: suppression of disesae activity and acute phase response. Arthritis Rheum 1996; 39:S244.

    Google Scholar 

  135. Choy EHS, Connolly DJA, Regan T, et al. T cell hypothesis in rheumatoid arthritis (RA) tested by humanized non-depleting anti-CD4 monoclonal antibody (mAb) treatment II: clinical activity is related to pharmacodynamic effects. Arthritis Rheum 1996; 39:S244.

    Article  Google Scholar 

  136. Wendling D, Racadot E, Wijdenes J, et al. A randomized, double blind, placebo controlled multicenter trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 1998; 25:1457–1461.

    PubMed  CAS  Google Scholar 

  137. Levy R, Weisman M, Wiesenhutter C, et al. Results of a placebo-controlled, multicenter trial using a primatized non-depleting, anti-CD4 monoclonal antibody in the treatment of rheumatoid arthritis. Arthritis Rheum 1996;39:S122.

    Google Scholar 

  138. Choy EHS, Connolly DJA, Rapson N, Kingsley GH, Johnston JM, Panayi GS: Effect of a humanised non-depleting anti-CD4 monoclonal antibody (mAb) on synovial fluid (SF) in rheumatoid arthritis (RA). Arthritis Rheum 1997;40:S52.

    Google Scholar 

  139. Schulze-Koops H, Davis LS, Haverty TP, Wacholtz MC, Lipsky PE. Reduction of Th1 cell activity in the peripheral circulation of patients with rheumatoid arthritis after treatment with a non-depleting humanized monoclonal antibody to CD 4. J Rheumatol 1998; 25:2065–2076.

    PubMed  CAS  Google Scholar 

  140. Olsen NJ, Brooks RY, Cush JJ, et al. A double-blind, placebo-controlled study of anti-Dd5 immunoconjugate in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39:1102–1108.

    Article  PubMed  CAS  Google Scholar 

  141. Kirkham BW, Pitzalis C, Kingsley GH, et al. Monoclonal antibody treatment in rheumatoid arthritis: the clinical and immunological effects of a CD7 monoclonal antibody. Br J Rheumatol 1991; 30:459–463.

    Article  PubMed  CAS  Google Scholar 

  142. Kirkham BW, Thien F, Pelton BK, et al. Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 1992;19:1348–1352.

    PubMed  CAS  Google Scholar 

  143. Lazarovits AI, White MJ, Karsh J. CD7-T cells in rheumatoid arthritis. Arthritis Rheum 1992; 35:615–624.

    Article  PubMed  CAS  Google Scholar 

  144. Choy EHS, Kingsley GH, Panayi GS. Monoclonal antibody therapy in rheumatoid arthritis. Br J Rheumatol 1998; 37:484–490.

    Article  PubMed  CAS  Google Scholar 

  145. Wardrop RM, Whitacre CC. Oral tolerance in the treatment of inflammatory autoimmune diseases. Inflamm Res 1999; 48:106–119.

    Article  PubMed  CAS  Google Scholar 

  146. Garside P, Mcl Mowat A. Mechanisms of oral tolerance. Crit Rev Immunol 1997; 17:119–137.

    Article  PubMed  CAS  Google Scholar 

  147. Xiao B-G, Link H. Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. Clin Immunol Immunopathol 1997; 85:119–128.

    Article  PubMed  CAS  Google Scholar 

  148. Mayer L. Oral Tolerance: new approaches, new problems. Clin Immunol 2000; 94:1–8.

    Article  PubMed  CAS  Google Scholar 

  149. Liblau R, Tisch R, Bercovici N, McDevitt HO. Systemic antigen in the treatment of T-cell-mediated autoimmune diseases. Immunology Today 1997; 18:599–604.

    Article  PubMed  CAS  Google Scholar 

  150. Karin N, Binah O, Grabie N, et al. Short peptide-based tolerogens without self-antigenic or pathogenic activity reverse autoimmune disease. J Immunol 1998; 160:5188–5194.

    PubMed  CAS  Google Scholar 

  151. Nicholson LB, Greer JM< Sobel RA, Lees MB, Kuchroo VK. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995; 3:397–405.

    Article  PubMed  CAS  Google Scholar 

  152. Brocke S, Gijbels K, Allegretta M, et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996; 379:343–346.

    Article  PubMed  CAS  Google Scholar 

  153. Husby S, Mestecky J, Moldoveanu Z, Holland S, Elson CO. Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. J Immunol 1994; 152:4663–4670.

    PubMed  CAS  Google Scholar 

  154. Trentham DE, Dynesius-Trentham RA, Orav EJ, et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993; 261:1727–1730.

    Article  PubMed  CAS  Google Scholar 

  155. Nussenblatt RB, Gery I, Weiner HL, et al. Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Amer J Ophthalmol 1997; 123:583–592.

    CAS  Google Scholar 

  156. Weiner HL, Makin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259:1321–1324.

    Article  PubMed  CAS  Google Scholar 

  157. Barnett ML, Kremer JM, St. Clair EW, et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 1998; 41:290–297.

    Article  PubMed  CAS  Google Scholar 

  158. Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA. Antigenspecific TGF-beta 1 secretion with bovine myelin oral tolerization in multiple sclerosis. Ann NY Acad Sci 1996; 778:251–257.

    Article  PubMed  CAS  Google Scholar 

  159. Gold DP, Shroeder K, Goldring A, Brostoff SW, Wilson DB. T-cell receptor peptides as immunotherapy for autoimmune disease. Crit Rev Immunol. 1997;17:507–510.

    PubMed  CAS  Google Scholar 

  160. Stinnisen P, Raus J. Autoreactive T cells in multiple sclerosis: pathogenetic role and therapeutic targeting. Acta Neurol Belgica 1999; 99:65–69.

    Google Scholar 

  161. McFarland HF, Hurley CK. Diversity of T-cell receptor Vα, Vβ, and CDR3 expression by myelin basic protein-specific human T-cell clones. Neurology 1995; 45: 1919–1922.

    Article  PubMed  Google Scholar 

  162. Zhang J, Medaer R, Stinissen P. Hafler D, Raus J. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 1993; 261:1451–1454.

    Article  PubMed  CAS  Google Scholar 

  163. Zhang J, Raus J. Clonal depletion of human myelin basic protein-reactive T-cells by T-cell vaccination. Ann N Y Acad Sci 1995; 755:323–326.

    Article  Google Scholar 

  164. Rosloniec EF, Brand DD, Whittington KB, Stuart JM, Ciubotaru M, Ward ES. Vaccination with a recombinant Va domain of a TCR prevents the development of collagen-induced arthritis. J Immunol 1995; 155:4504–4511.

    PubMed  CAS  Google Scholar 

  165. Iverson GM, Jones DS, Marquis D, Linnik MD, Victoria EJ. A chemically defined, toleragen-based approach for targeting anti-beta2-glycoprotein I antibodies. Lupus 1998; 2:S166–S169.

    Article  Google Scholar 

  166. Jones DS, Barstad PA, Feild MJ, et al. Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis. J Medicinal Chem 1995; 38:2138–2144.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

    Timothy M. Wright & Dana P. Ascherman

Authors
  1. Timothy M. Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dana P. Ascherman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Pittsburgh, Pittsburgh, PA, USA

    Angus W. Thomson

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Wright, T.M., Ascherman, D.P. (2001). Therapy of Autoimmune Connective Tissue Diseases. In: Thomson, A.W. (eds) Therapeutic Immunosuppression. Immunology and Medicine Series, vol 29. Springer, Dordrecht. https://doi.org/10.1007/978-94-010-0765-8_14

Download citation

  • DOI: https://doi.org/10.1007/978-94-010-0765-8_14

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-3821-8

  • Online ISBN: 978-94-010-0765-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation